genetic diseases

Darts failing to hit bullseye

Pharma

Rhythm's Imcivree posts ph. 3 miss in rare genetic obesities

The company evaluated Imcivree across four genetic-driven obesity subgroups, with the treatment missing the primary BMI endpoint in each substudy.

Zoey Becker Mar 17, 2026 11:43am

opening door to brick wall

Fierce Biotech

Senate hearing takes aim at FDA's rare disease review process

Feb 26, 2026 3:50pm

failure crash no fail rocket cancelled end

Quince explores options after ph. 3 rare disease flop

Jan 30, 2026 10:44am

arrow bullseye target on target

Arrowhead strikes true with first FDA approval

Nov 18, 2025 3:44pm

FDA

FDA approves Soleno's Vykat XR for insatiable hunger disorder

Mar 27, 2025 11:24am

Ionis headquarters

Tryngolza's FDA approval marks 'pivotal moment' for Ionis: CEO

Dec 20, 2024 8:32am